CELLULAR BIOMEDICINE GROUP, INC. 1,029,412 Shares of Common Stock (par value $0.001 per share) Underwriting AgreementUnderwriting Agreement • March 22nd, 2019 • Cellular Biomedicine Group, Inc. • Biological products, (no disgnostic substances) • New York
Cellular Biomedicine Group, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 1,029,412 shares of its common stock, par value $0.001 per share (the “Shares”). The 1,029,412 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 154,411 Shares pursuant to such option are collectively called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Cantor Fitzgerald & Co. (“Cantor”) and Robert W. Baird & Co. Incorporated (“Baird”) have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term “R
